Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer

Amit D. Raval, Malcolm D. Mattes, Suresh Madhavan, Xiaoyun Pan, Wenhui Wei, Usha Sambamoorthi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective. To examine the association between metformin use and cancer stage at diagnosis among elderly men with preexisting diabetes mellitus and incident prostate cancer. Methods. This study used a population-based observational cohort of elderly men (≥66 years) with preexisting diabetes and incident prostate cancer between 2008 and 2009 (N = 2,652). Cancer stage at diagnosis (localized versus advanced) was based on the American Joint Cancer Committee classification. Metformin use and other independent variables were measured during the one year before cancer diagnosis. Logistic regressions with inverse probability treatment weights were used to control for the observed selection bias. Results. A significantly lower percentage of metformin users were diagnosed with advanced prostate cancer as compared to nonusers (4.7% versus 6.7%, p < 0.03). After adjusting for the observed selection bias and other independent variables, metformin use was associated with a 32% reduction in the risk of advanced prostate cancer (adjusted odds ratio, AOR: 0.68, 95% confidence interval, CI: 0.48, 0.97). Conclusions. This is the first epidemiological study to support the role of metformin in reducing the risk of advanced prostate cancer. Randomized clinical trials are needed to confirm the causal link between metformin use and prostate cancer diagnosis stage.

Original languageEnglish
Article number2656814
JournalJournal of Diabetes Research
Volume2016
DOIs
StatePublished - 1 Jan 2016

Fingerprint

Metformin
Medicare
Type 2 Diabetes Mellitus
Prostatic Neoplasms
Neoplasms
Selection Bias
Risk Reduction Behavior
Epidemiologic Studies
Diabetes Mellitus
Randomized Controlled Trials
Joints
Logistic Models
Odds Ratio
Confidence Intervals
Weights and Measures
Population

Cite this

@article{31e7ed52e5d64d5492b0963fb1d6f42d,
title = "Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer",
abstract = "Objective. To examine the association between metformin use and cancer stage at diagnosis among elderly men with preexisting diabetes mellitus and incident prostate cancer. Methods. This study used a population-based observational cohort of elderly men (≥66 years) with preexisting diabetes and incident prostate cancer between 2008 and 2009 (N = 2,652). Cancer stage at diagnosis (localized versus advanced) was based on the American Joint Cancer Committee classification. Metformin use and other independent variables were measured during the one year before cancer diagnosis. Logistic regressions with inverse probability treatment weights were used to control for the observed selection bias. Results. A significantly lower percentage of metformin users were diagnosed with advanced prostate cancer as compared to nonusers (4.7{\%} versus 6.7{\%}, p < 0.03). After adjusting for the observed selection bias and other independent variables, metformin use was associated with a 32{\%} reduction in the risk of advanced prostate cancer (adjusted odds ratio, AOR: 0.68, 95{\%} confidence interval, CI: 0.48, 0.97). Conclusions. This is the first epidemiological study to support the role of metformin in reducing the risk of advanced prostate cancer. Randomized clinical trials are needed to confirm the causal link between metformin use and prostate cancer diagnosis stage.",
author = "Raval, {Amit D.} and Mattes, {Malcolm D.} and Suresh Madhavan and Xiaoyun Pan and Wenhui Wei and Usha Sambamoorthi",
year = "2016",
month = "1",
day = "1",
doi = "10.1155/2016/2656814",
language = "English",
volume = "2016",
journal = "Journal of Diabetes Research",
issn = "2314-6745",
publisher = "Hindawi Limited",

}

Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer. / Raval, Amit D.; Mattes, Malcolm D.; Madhavan, Suresh; Pan, Xiaoyun; Wei, Wenhui; Sambamoorthi, Usha.

In: Journal of Diabetes Research, Vol. 2016, 2656814, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between Metformin Use and Cancer Stage at Diagnosis among Elderly Medicare Beneficiaries with Preexisting Type 2 Diabetes Mellitus and Incident Prostate Cancer

AU - Raval, Amit D.

AU - Mattes, Malcolm D.

AU - Madhavan, Suresh

AU - Pan, Xiaoyun

AU - Wei, Wenhui

AU - Sambamoorthi, Usha

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective. To examine the association between metformin use and cancer stage at diagnosis among elderly men with preexisting diabetes mellitus and incident prostate cancer. Methods. This study used a population-based observational cohort of elderly men (≥66 years) with preexisting diabetes and incident prostate cancer between 2008 and 2009 (N = 2,652). Cancer stage at diagnosis (localized versus advanced) was based on the American Joint Cancer Committee classification. Metformin use and other independent variables were measured during the one year before cancer diagnosis. Logistic regressions with inverse probability treatment weights were used to control for the observed selection bias. Results. A significantly lower percentage of metformin users were diagnosed with advanced prostate cancer as compared to nonusers (4.7% versus 6.7%, p < 0.03). After adjusting for the observed selection bias and other independent variables, metformin use was associated with a 32% reduction in the risk of advanced prostate cancer (adjusted odds ratio, AOR: 0.68, 95% confidence interval, CI: 0.48, 0.97). Conclusions. This is the first epidemiological study to support the role of metformin in reducing the risk of advanced prostate cancer. Randomized clinical trials are needed to confirm the causal link between metformin use and prostate cancer diagnosis stage.

AB - Objective. To examine the association between metformin use and cancer stage at diagnosis among elderly men with preexisting diabetes mellitus and incident prostate cancer. Methods. This study used a population-based observational cohort of elderly men (≥66 years) with preexisting diabetes and incident prostate cancer between 2008 and 2009 (N = 2,652). Cancer stage at diagnosis (localized versus advanced) was based on the American Joint Cancer Committee classification. Metformin use and other independent variables were measured during the one year before cancer diagnosis. Logistic regressions with inverse probability treatment weights were used to control for the observed selection bias. Results. A significantly lower percentage of metformin users were diagnosed with advanced prostate cancer as compared to nonusers (4.7% versus 6.7%, p < 0.03). After adjusting for the observed selection bias and other independent variables, metformin use was associated with a 32% reduction in the risk of advanced prostate cancer (adjusted odds ratio, AOR: 0.68, 95% confidence interval, CI: 0.48, 0.97). Conclusions. This is the first epidemiological study to support the role of metformin in reducing the risk of advanced prostate cancer. Randomized clinical trials are needed to confirm the causal link between metformin use and prostate cancer diagnosis stage.

UR - http://www.scopus.com/inward/record.url?scp=84986275058&partnerID=8YFLogxK

U2 - 10.1155/2016/2656814

DO - 10.1155/2016/2656814

M3 - Article

C2 - 27547763

AN - SCOPUS:84986275058

VL - 2016

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

SN - 2314-6745

M1 - 2656814

ER -